Provided by Tiger Fintech (Singapore) Pte. Ltd.

ADC Therapeutics SA

1.79
+0.200012.58%
Post-market: 1.71-0.0800-4.47%19:00 EST
Volume:588.16K
Turnover:975.12K
Market Cap:173.07M
PE:-0.77
High:1.79
Open:1.58
Low:1.50
Close:1.59
Loading ...

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
27 Feb

Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
25 Feb

ADC Therapeutics Is Maintained at Overweight by Stephens & Co.

Dow Jones
·
24 Feb

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

PR Newswire
·
04 Feb

ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

PR Newswire
·
30 Jan

Jefferies Reaffirms Their Buy Rating on ADC Therapeutics (ADCT)

TIPRANKS
·
24 Jan

ADC Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Jan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

PR Newswire
·
03 Jan

Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial

MT Newswires Live
·
01 Jan

ADC Completes Enrollment in Late-Stage Zynlonta Combination Trial

MT Newswires Live
·
31 Dec 2024

BRIEF-Adc Therapeutics Announces Completion Of Enrollment Of Phase 3 Confirmatory Clinical Trial Of Zynlonta In Combination With Rituximab In 2L+ Diffuse Large B-Cell Lymphoma

Reuters
·
31 Dec 2024

ADC Therapeutics completes enrollment in LOTIS-5 trial

TIPRANKS
·
31 Dec 2024

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of Zynlonta® in Combination With Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
31 Dec 2024

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

PR Newswire
·
31 Dec 2024

ADC Therapeutics Price Target Maintained With a $10.00/Share by Guggenheim

Dow Jones
·
12 Dec 2024

ADC Therapeutics falls -8.9%

TIPRANKS
·
11 Dec 2024